These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6528867)

  • 21. Methyl-GAG in patients with malignant neoplasms: a phase I re-evaluation.
    Hart RD; Ohnuma T; Holland JF; Bruckner H
    Cancer Treat Rep; 1982 Jan; 66(1):65-71. PubMed ID: 7053268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of [14C]methylglyoxal-bis-guanylhydrazone) in patients with leukemia.
    Rosenblum MG; Keating MJ; Yap BS; Loo TL
    Cancer Res; 1981 May; 41(5):1748-50. PubMed ID: 7214342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer.
    Yap HY; Blumenschein GR; Schell F; Bodey GP
    Cancer Treat Rep; 1981; 65(5-6):465-7. PubMed ID: 7237467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methyl-GAG in advanced colon cancer: a phase II trial of the Southwest Oncology Group.
    Knight WA; Loesch DM; Leichman LP; Fabian C; O'Bryan RM
    Cancer Treat Rep; 1982 Dec; 66(12):2099-100. PubMed ID: 7139653
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II trial of mitoguazone in patients with advanced head and neck cancer.
    Thongprasert S; Bosl GJ; Geller NL; Wittes RE
    Cancer Treat Rep; 1984 Oct; 68(10):1301-2. PubMed ID: 6525604
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase I study of alpha-difluoromethylornithine and methyl-GAG.
    Splinter TA; Romijn JC
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):61-7. PubMed ID: 3082642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of methyl-GAG in advanced renal cancer.
    Zeffren J; Yagoda A; Watson RC; Natale RB; Blumenreich MS; Chapman R; Howard J
    Cancer Treat Rep; 1981; 65(5-6):525-7. PubMed ID: 6263478
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract.
    Barrett JT; Orofiamma B; Khandekar JD; Carbone PP; Comis RL; Davis TE
    Cancer; 1989 Dec; 64(12):2445-7. PubMed ID: 2684384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft-tissue sarcomas.
    Sordillo PP; Magill GB; Welt S
    Am J Clin Oncol; 1985 Aug; 8(4):316-8. PubMed ID: 3909804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition of methylglyoxal bis(guanylhydrazone) (MGBG, NSC-32946) in man.
    Stewart DJ; Rosenblum MG; Luna M; Loo TL
    Cancer Chemother Pharmacol; 1981; 7(1):31-5. PubMed ID: 6280886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of methylglyoxal bis(guanylhydrazone) on tumour and skin responses to hyperthermia in mice.
    Miyakoshi J; Hiraoka M; Oda W; Takahashi M; Abe M; Inagaki C
    Int J Radiat Biol Relat Stud Phys Chem Med; 1984 Sep; 46(3):287-91. PubMed ID: 6333410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of mitoguazone in patients with refractory germ cell tumors.
    Chun H; Bosl GJ
    Cancer Treat Rep; 1985 Apr; 69(4):461-2. PubMed ID: 2986835
    [No Abstract]   [Full Text] [Related]  

  • 33. Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer.
    Herr HW; Kleinert EL; Relyea NM; Whitmore WF
    Cancer; 1984 Mar; 53(6):1294-8. PubMed ID: 6420041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of methyl-GAG (NSC-32946) in squamous cell and adenocarcinoma of the lung.
    Samson MK; Baker LH; Cummings G; Talley RW
    Am J Clin Oncol; 1982 Dec; 5(6):631-3. PubMed ID: 7165005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of alpha-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancer.
    Herr HW; Warrel RP; Burchenal JH
    Urology; 1986 Dec; 28(6):508-11. PubMed ID: 3097903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)].
    Warrell RP; Coonley CJ; Burchenal JH
    Cancer Chemother Pharmacol; 1983; 11(2):134-6. PubMed ID: 6414731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of mitogauzone in malignant primary brain tumors.
    Feun LG; Yung WK; Stewart DJ; Savaraj N; Bodey GP
    Cancer Treat Rep; 1985 Mar; 69(3):329-30. PubMed ID: 3978660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.
    Levine AM; Tulpule A; Tessman D; Kaplan L; Giles F; Luskey BD; Scadden DT; Northfelt DW; Silverberg I; Wernz J; Espina B; Von Hoff D
    J Clin Oncol; 1997 Mar; 15(3):1094-103. PubMed ID: 9060550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of patients with refractory myelogenous leukemia with BCOMM[1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)].
    Herman TS; Durie BG; Hutter JJ
    Cancer Chemother Pharmacol; 1982; 8(1):73-5. PubMed ID: 6954016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of mitoguazone in patients with relapsed small cell carcinoma of the lung.
    Scher H; Chapman R; Kelsen D; Gralla R; Wittes R
    Cancer Treat Rep; 1984 Mar; 68(3):561-2. PubMed ID: 6322989
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.